Is Mounjaro Available in Tablet Form in the UK?

You've searched 'Mounjaro tablet', here is what that search actually finds

Lots of people arrive at this question after seeing posts about oral weight-loss medicines, or after a pharmacist mentioned that a tablet version exists. The confusion is understandable. In June 2026, the MHRA approved Wegovy tablets (oral semaglutide) as the UK's first injectable-free GLP-1 option for weight management. That is genuinely new and genuinely significant. But semaglutide and tirzepatide are different molecules. Wegovy tablets contain semaglutide; Mounjaro contains tirzepatide. The two drugs share a class and a general mechanism, but they are not interchangeable, and one becoming available in tablet form does not mean the other has followed.

If the question you are really asking is whether tirzepatide is available in pill form anywhere in the world, the answer is still no. Research into oral tirzepatide is ongoing, but no regulator (including the MHRA, the FDA or the EMA) has approved a tablet version as of summer 2026. The oral tirzepatide question has a longer answer worth reading if you want the full picture on the pipeline.

For now, if someone is offering you Mounjaro in tablet or capsule form, that is not a licensed product. It should be treated as a red flag.

Why tirzepatide is harder to put in a tablet than semaglutide

Turning a GLP-1 or dual-agonist into a tablet is genuinely difficult chemistry. These are large peptide molecules that the digestive system would normally break down before they reach the bloodstream. Novo Nordisk solved this for semaglutide by co-formulating it with an absorption enhancer called SNAC, which allows the drug to pass through the stomach lining intact, and even then, the Wegovy tablet must be taken first thing in the morning on an empty stomach, with a small sip of water, at least 30 minutes before food or any other medicine. The bioavailability challenges for tirzepatide as a larger, dual-agonist molecule are at least as significant. Eli Lilly has not publicly confirmed a development timeline for an oral version, and when a Mounjaro tablet might reach the UK remains genuinely unknown.

That does not mean it will never happen. Pharmaceutical development in this space is moving quickly. But speculating beyond what the evidence shows would not be useful to you.

What this means practically: if a tablet matters to you (perhaps because of needle anxiety, or travel, or daily routine) the licensed injectable-free option available right now is the Wegovy tablet, not Mounjaro. A prescriber can help you weigh up whether that suits your situation better than an injection.

What Mounjaro actually is, and what the evidence says about it

Because this question often comes from people who have only recently encountered the name, it is worth being clear about what Mounjaro is. Tirzepatide activates two receptors involved in appetite regulation and blood-sugar control (GIP and GLP-1) which is why it is described as a dual agonist and why it is the only medicine of its kind licensed for weight management in the UK. It is approved by the MHRA for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure or type 2 diabetes, used alongside a reduced-calorie diet and increased physical activity.

In the SURMOUNT-1 trial (a 72-week study in adults with obesity) participants on the highest dose achieved an average body-weight reduction of around 20 to 21%, as reported in the New England Journal of Medicine. NICE reviewed that evidence and recommended tirzepatide for NHS use in eligible patients. Privately, it is available through a GPhC-registered pharmacy following a prescriber assessment. The medicine comes as a once-weekly injection: a pre-filled KwikPen that you use at home, with the used pen going into a sharps bin. When you order through a regulated service, the pen arrives via tracked DPD delivery the next working day in plain, unbranded packaging, there is nothing on the box to indicate what is inside.

The NHS medicines page for tirzepatide covers storage, common side effects and what to discuss with your prescriber before starting.

How the tablet question shapes your actual decision

People looking into whether Mounjaro exists in a tablet form are often, underneath the question, asking something else: is there a version of this treatment I could take without injecting myself? That is a legitimate and very common concern. The answer in 2026 is yes, but the tablet is a different medicine (semaglutide, not tirzepatide), and it carries its own evidence base, its own dosing schedule and its own clinical profile.

Choosing between an oral and an injectable GLP-1 medicine is a clinical conversation, not a consumer preference. The two medicines have different trial histories, different mechanisms and different eligibility criteria. Questions about which approach might suit you better (or whether you meet the criteria for either) are exactly the kind of thing our prescribers work through with patients at consultation. You can read more about cost context on the Mounjaro pricing page if that is also part of your thinking. For the tablet specifically, the Mounjaro UK availability page gives broader context on the injectable and how it is accessed here.

If you would like a prescriber to assess your options, start your free consultation and a GPhC-registered clinician will review your answers the same day.